| |
|
|
|
|
|
 |
| |
|
À¯¸®½ºÄµ10¿¡½ºÁö¿¤½ÃÇèÁöÄÉÅæÃ¼ URISCAN 10 SGL STRIP[Sodium hydrogen phosphate , Sodium nitroprusside]
|
Àü¹®ÀǾàǰ | »èÁ¦ | ºÐ¾÷¿¹¿ÜÀǾàǰ(41)
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A14401251]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1¸Å(2007.03.01)(ÇöÀç¾à°¡)
\0 ¿ø/1¸Å(2005.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
÷ºÎµÈ ºñ»öÇ¥¿¡ ÇØ´çÇÏ´Â »ö»óÀ» °¡Áø Á¤»ç°¢Çü ½ÃÇèÁö°¡ °¢°¢ ÇÃ¶ó½ºÆ½ Çʸ§¿¡ ºÎÂøµÈ ½ºÆ®¸³
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
100¸Å |
| º¸°ü¹æ¹ý |
Â÷±¤±â¹Ð¿ë±â, 2-30¡É, 24°³¿ù
(°¨µµ°¡ ÀúÇϵÇÁö ¾Êµµ·Ï ½À±â, Á÷»çÀϱ¤, ¿À» ÇÇÇØ ¹ÐÀüÇÏ¿© Àú¿Â, °ÇÁ¶ÇÑ Àå¼Ò¿¡ º¸Á¸ÇÑ´Ù. ´Ü, ³ÃÀ庸Á¸Àº ÇÇÇÒ °Í) |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´¢ ´Ü¹éÁú, Æ÷µµ´ç, PH, ¿ì·Îºô¸®³ë°Õ, ºô¸®·çºó, ÄÉÅæÃ¼, ÀáÇ÷, ¾ÆÁú»ê¿°, ºñÁß, ¹éÇ÷±¸ µ¿½Ã °Ë»ç¿ë ½ÃÇèÁö.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
- ´¢¸¦ ¿ë±â¿¡ ¸ð¾Æ »ç¿ë Àü Èçµé°í ½ÃÇèÁöÀÇ ½ÃÇèºÎºÐÀ» ´¢¿¡ ħÀû½ÃŲ ÈÄ ²¨³½´Ù.
- °úÀ×ÀÇ ´¢¸¦ Èí¼öÁö¿¡ ´ë¾î Á¦°ÅÇÑ´Ù.
- 60ÃÊ(¹éÇ÷±¸ ½ÃÇèºÎºÐÀº 9-120ÃÊ)¿¡ ½ÃÇèºÎºÐÀÇ ¹ß»öÁ¤µµ¸¦ ¿ë±â¿¡ ºÎÂøµÈ ºñ»öÇ¥¿Í ºñ±³ÇÏ¿© ÆÇÁ¤ÇÑ´Ù. ´Ü, ´¢»ö¿¡ ÀÇÇÏ¿© ºñ»öÇ¥¿Í Â÷À̰¡ ³¯ °æ¿ì¿¡´Â °¡±ÞÀû À¯»çÇÑ ºñ»öÇ¥ÀÇ »ö´ë·Î ÆÇÁ¤ÇÑ´Ù.
- ´¢ºÐ¼®±â¸¦ ÀÌ¿ëÇÏ¿© ÃøÁ¤ÇÒ °æ¿ì¿¡´Â ºÐ¼®±âÀÇ ÀÛµ¿¹ý¿¡ µû¶ó ½Ç½ÃÇÑ´Ù.
|
| ÀϹÝÀû ÁÖÀÇ |
- ü¿ÜÁø´Ü¿ëÀ¸·Î¸¸ »ç¿ëÇÑ´Ù.
- ´¢ ºÐ¼®±â¸¦ ÀÌ¿ëÇÏ¿© ÆÇÁ¤ÇÒ °æ¿ì¿¡´Â »ç¿ë ºÐ¼®±âÀÇ ¼³¸í¼¸¦ ÁÖÀÇ ±í°Ô ÀÐ°í ³ ÈÄ »ç¿ëÇÑ´Ù.
- °¨µµ°¡ ÀúÇϵÇÁö ¾Êµµ·Ï ½À±â, Á÷»ç±¤¼±, ¿À» ÇÇÇØ¼ º¸Á¸ÇÑ´Ù.
- Àú¿ÂÀÇ °ÇÁ¶ÇÑ °÷¿¡ º¸Á¸ÇÏ°í ³ÃÀ庸Á¸ÇÏÁö ¾Ê´Â´Ù.
- ¿ë±â³»ÀÇ °ÇÁ¶Á¦´Â º¸Á¸ÇÏ°í ¿ÜºÎ·Î ²¨³»Áö ¾Ê´Â´Ù.
- ½ÃÇèÁö´Â ÇÊ¿äÇÑ ¸Å¼ö¸¸ ²¨³»°í Áï½Ã ¹ÐÀüÇÑ´Ù.
- ½ÃÇè ºÎºÐ¿¡ ¼ÕÀ» ´ë°Å³ª Ã¥»ó, ½ÃÇè´ë À§¿¡ Á÷Á¢ ½ÃÇèÁö¸¦ ³õÁö ¾Ê´Â´Ù.
- ½ÃÇè ºÎºÐÀÌ º¯»öµÈ °ÍÀ» »ç¿ëÇÏÁö ¾Ê´Â´Ù.
- Èֹ߼º ¾àǰ¿¡ ÀÇÇÑ ½ÃÇèÁöÀÇ ¿ëÃâÀ» ¹æÁöÇϱâ À§ÇÏ¿© ´¢¸¦ ħÀû½ÃŲ Áï½Ã ²¨³»¾ß ÇÑ´Ù.
- ½ÃÇèÁö ºÎºÐÀÇ ½Ã¾à ¿ëÃâÀ» ¹æÁöÇϱâ À§ÇÏ¿© ´¢¸¦ ħÀû½ÃŲ Áï½Ã ²¨³»¾ß ÇÑ´Ù.
- À°¾È ÆÇÁ¤ÀÇ °æ¿ì ½ÃÇè °á°ú´Â ±ÔÁ¤ÇÑ ½ÃÇè½Ã°£À» ÁöŰ°í ¹àÀº ±¤¼± Á¶°Ç ÇÏ¿¡¼ ºñ»öÇ¥ÀÇ »ö´ë¿Í ºñ±³ÇÏ¿© ÆÇÁ¤ÇÑ´Ù.
- ÆÇÁ¤¿¡ ÀÖ¾î¼ ½ÃÇè ºÎºÐÀÇ ¹ÝÀÀÀº ³»Àμº ÃËÁø¹°°ú ÀúÇØ¹°Áú À̿ܿ¡µµ ¹ÝÀÀ°¨µµ³ª ½ÃÇèÁöÀÇ Á¶°Ç µî¿¡ ÀÇÇØ ¿µÇâÀ» ¹Þ±â ¶§¹®¿¡ Ç¥½ÃµÈ ³óµµ´Â ´ëüÀûÀÎ ÁöÇ¥·Î Çϰí 1´Ü°è »óÇϹüÀ§ Á¤µµÀÇ º¯µ¿ÀÌ »ý±æ °¡´É¼ºÀ» °í·ÁÇØ µÎ´Â ÆíÀÌ ¾ÈÀüÇÏ´Ù.
- ºñŸ¹Î ¾¾¸¦ ´ë·®À¸·Î ¼·ÃëÇϰí Àִ ȯÀÚÀÇ ´¢¿¡¼´Â ¹ÝÀÀÀÌ ¾ïÁ¦µÇ°Å³ª Áö¿¬µÇ¾î¼ Á¤È®ÇÑ °á°ú¸¦ ¾òÀ» ¼ö ¾ø´Â °æ¿ì°¡ ÀÖ´Ù. ±×·¯³ª ºñŸ¹Î ¾¾ À̿ܿ¡´Â °¢Á¾ ¾àÁ¦ÀÇ Åõ¿©¿¡ ´ëÇÑ ¿µÇâÀº È®½ÇÇÏÁö ¾Ê´Ù.
- äÃëÇÑ °Ëü´Â °Ëü äÃë ÈÄ 1½Ã°£ À̳»¿¡ °Ë»çÇϸç ÃøÁ¤ÀÌ °ï¶õÇÒ ½Ã´Â Áï½Ã ³ÃÀåÇϰí, ÃøÁ¤ Àü¿¡ ½Ç¿ÂÀ¸·Î ÇÏ¿© »ç¿ëÇÑ´Ù.
|
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
Â÷±¤±â¹Ð¿ë±â, 2-30¡É, 24°³¿ù
(°¨µµ°¡ ÀúÇϵÇÁö ¾Êµµ·Ï ½À±â, Á÷»çÀϱ¤, ¿À» ÇÇÇØ ¹ÐÀüÇÏ¿© Àú¿Â, °ÇÁ¶ÇÑ Àå¼Ò¿¡ º¸Á¸ÇÑ´Ù. ´Ü, ³ÃÀ庸Á¸Àº ÇÇÇÒ °Í) |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A14401251]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1¸Å(2007.03.01)(Ãֽžడ)
\0 ¿ø/1¸Å(2005.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
÷ºÎµÈ ºñ»öÇ¥¿¡ ÇØ´çÇÏ´Â »ö»óÀ» °¡Áø Á¤»ç°¢Çü ½ÃÇèÁö°¡ °¢°¢ ÇÃ¶ó½ºÆ½ Çʸ§¿¡ ºÎÂøµÈ ½ºÆ®¸³
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
100¸Å |
| º¸°ü¹æ¹ý |
Â÷±¤±â¹Ð¿ë±â, 2-30¡É, 24°³¿ù
(°¨µµ°¡ ÀúÇϵÇÁö ¾Êµµ·Ï ½À±â, Á÷»çÀϱ¤, ¿À» ÇÇÇØ ¹ÐÀüÇÏ¿© Àú¿Â, °ÇÁ¶ÇÑ Àå¼Ò¿¡ º¸Á¸ÇÑ´Ù. ´Ü, ³ÃÀ庸Á¸Àº ÇÇÇÒ °Í) |
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(nitroprusside; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
nitroprusside¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ One molecule of sodium nitroprusside is metabolized by combination with hemoglobin to produce one molecule of cyanmethemoglobin and four CN- ions; methemoglobin, obtained from hemoglobin, can sequester cyanide as cyanmethemoglobin; thiosulfate reacts with cyanide to produce thiocyanate; thiocyanate is eliminated in the urine; cyanide not otherwise removed binds to cytochromes. Cyanide ion is normally found in serum; it is derived from dietary substrates and from tobacco smoke. Cyanide binds avidly (but reversibly) to ferric ion (Fe+++), most body stores of which are found in erythrocyte methemoglobin (metHgb) and in mitochondrial cytochromes. When CN is infused or generated within the bloodstream, essentially all of it is bound to methemoglobin until intraerythrocytic methemoglobin has been saturated.
|
| Pharmacology |
nitroprusside¿¡ ´ëÇÑ Pharmacology Á¤º¸ Nitroprusside a powerful vasodilator relaxes the vascular smooth muscle and produce consequent dilatation of peripheral arteries and veins. Other smooth muscle (e.g., uterus, duodenum) is not affected. Sodium nitroprusside is more active on veins than on arteries.
|
| Half-life |
nitroprusside¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Approximately 2 minutes
|
| Pharmacokinetics |
Sodium nitroprussideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Ç÷¾Ð°ÇÏ ÀÛ¿ë¹ßÇö½Ã°£ : 2ºÐ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : Ä¡·á Áß´ÜÈÄ 1-10ºÐ À̳»¿¡ È¿°ú°¡ »ç¶óÁü
- ´ë»ç : nitroprusside´Â Ç÷¾×¿¡¼ cyanide·Î ÀüȯµÇ°í prussic acid´Â sulfur±âÀÇ Á¸Àç½Ã thiocyanate·Î ÀüȯµÊ(°£, ½ÅÀåÀÇ rhodanase system).
- ¹Ý°¨±â
- ¿ø¼ººÐ : 10ºÐ À̳»
- thiocyanate : 2.7-7ÀÏ
- ¹è¼³ : thiocyanate : ½Å ¹è¼³
|
| Biotransformation |
nitroprusside¿¡ ´ëÇÑ Biotransformation Á¤º¸ Metabolized by reaction with hemoglobin to produce cyanmethemoglobin and cynide ions
|
| Toxicity |
nitroprusside¿¡ ´ëÇÑ Toxicity Á¤º¸ Overdosage of nitroprusside can be manifested as excessive hypotension or cyanide toxicity or as thiocyanate toxicity. The acute intravenous mean lethal doses (LD50) of nitroprusside in rabbits, dogs, mice, and rats are 2.8, 5.0, 8.4, and 11.2 mg/kg, respectively.
|
| Drug Interactions |
nitroprusside¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
nitroprusside¿¡ ´ëÇÑ Description Á¤º¸ Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency. [Wikipedia]
|
| Dosage Form |
nitroprusside¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Powder, for solution Intravenous
|
| Drug Category |
nitroprusside¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antihypertensive AgentsIndicators and ReagentsNitric Oxide DonorsVasodilator Agents
|
| Smiles String Canonical |
nitroprusside¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ [Fe+4].[N-]=O.[C-]
|
| Smiles String Isomeric |
nitroprusside¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ [Fe+4].[N-]=O.[C-]
|
| InChI Identifier |
nitroprusside¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/5CN.Fe.NO/c5*1-2;;1-2/q5*-1;+4;-1
|
| Chemical IUPAC Name |
nitroprusside¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ iron(+4) cation; oxoazanide; pentacyanide
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2012-03-02
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|